Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Cindy McCully"'
Autor:
Jette Tjørnelund, Cindy McCully, Frank M. Balis, Katherine E. Warren, Henrik Dvinge, Henri S. Lichenstein, Maxwell Sehested
Publikováno v:
Cancer Chemotherapy and Pharmacology. 62:433-437
Histone deacetylases (HDAC) are involved in the regulation of gene transcription. Aberrant HDAC activity has been associated with tumorigenesis, and, therefore, HDACs are potential targets for the treatment of cancers, including tumors of the central
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6a816dc43774cfab617d213893cd4ea
https://doi.org/10.1007/s00280-007-0622-5
https://doi.org/10.1007/s00280-007-0622-5
Autor:
Karen Godwin, Barry D. Anderson, Philip A. Pizzo, Brigitta U. Mueller, Cindy McCully, Hiroaki Mitsuya, Judy Zuckerman, Frank M. Balis, Paul Jarosinski, Maureen Farley, Robert L. Murphy
Publikováno v:
Antimicrobial Agents and Chemotherapy. 42:1815-1818
KNI-272 is a human immunodeficiency virus (HIV) protease inhibitor with potent activity in vitro. We studied the pharmacokinetics of KNI-272 in the plasma and cerebrospinal fluid (CSF) of a nonhuman primate model and after intravenous and oral admini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe3e6c142a4b36c8f314f5ef4eb4248b
https://doi.org/10.1128/aac.42.7.1815
https://doi.org/10.1128/aac.42.7.1815
Autor:
Cindy McCully, Katherine E. Warren, Nalini Jayaprakash, Anandani Nellan, Daniel W. Lee, Brigitte C. Widemann
Publikováno v:
Cancer Research. 76:1411-1411
Background: Cytokine release syndrome (CRS) is a life-threatening complication of effective immunotherapies, particularly chimeric antigen receptor (CAR) T-cells. CRS is characterized by fever, hypotension, cardiac dysfunction, and at times end organ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::189efb84eddf47f4e6500a4b34b17acf
https://doi.org/10.1158/1538-7445.am2016-1411
https://doi.org/10.1158/1538-7445.am2016-1411
Autor:
Diane E. Cole, AeRang Kim, Elizabeth Fox, Raphael Cruz, Frank M. Balis, Cindy McCully, Brigitte C. Widemann
Publikováno v:
Investigational new drugs. 30(2)
Purpose Sorafenib is a small molecule inhibitor of multiple signaling kinases thought to contribute to the pathogenesis of many tumors including brain tumors. Clinical trials with sorafenib in primary and metastatic brain tumors are ongoing. We evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffbfe561e910efabdf4f7ccd3c6659c4
https://pubmed.ncbi.nlm.nih.gov/21072558
https://pubmed.ncbi.nlm.nih.gov/21072558
Publikováno v:
Cancer chemotherapy and pharmacology. 44(6)
Purpose: Raltitrexed (Tomudex™), ZD1694) is a novel quinazoline folate analog that selectively inhibits thymidylate synthase. Intracellularly, raltitrexed is polyglutamated to its active form which can be retained in cells for prolonged periods. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f1ad9524bc1bc4f9f94ccb52e457955
https://pubmed.ncbi.nlm.nih.gov/10550563
https://pubmed.ncbi.nlm.nih.gov/10550563
Autor:
AeRang Kim, Cindy McCully, Rafael Cruz, Diane E. Cole, Elizabeth Fox, Frank M. Balis, Brigitte C. Widemann
Publikováno v:
Cancer Research. 70:1672-1672
Background: Sorafenib is an oral multikinase inhibitor that targets intracellular and receptor protein kinases thought to be crucial in the pathogenesis and growth of many tumors including brain tumors. Sorafenib is FDA approved for advanced renal ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9771f2c4c9161cd93aebee0b36ba16db
https://doi.org/10.1158/1538-7445.am10-1672
https://doi.org/10.1158/1538-7445.am10-1672